New drug combo aims to fight Hard-to-Treat colorectal cancer

NCT ID NCT06992258

Recruiting now Disease control Sponsor: Criterium, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two drugs—fruquintinib and TAS-102—works better than fruquintinib alone for people with advanced colorectal cancer that hasn't responded to prior treatments. About 120 adults will be randomly assigned to one of the two groups. The main goal is to see if the combination delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fruquintinib and TAS-102 (trifluridine and tipiracil)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to other therapies.
What could go wrong: This is a phase 2 trial with only 120 participants, so results are preliminary. The combination may not improve survival and could cause more side effects than the single drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Inova Schar Cancer
RECRUITING

Fairfax, Virginia, 22031, United States
Mays Cancer Center at University of Texas Health at San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Mount Sinai Cancer Research Program
RECRUITING

Miami Beach, Florida, 33140, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Orlando Health Cancer Institute
RECRUITING

Orlando, Florida, 32806, United States
Rutgers Cancer Institute
RECRUITING

New Brunswick, New Jersey, 08903, United States
UPenn Lancaster-Ann B. Barshinger Cancer Institute
RECRUITING

Lancaster, Pennsylvania, 17601, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.